You are here: Industry Insights > Astellas

News List

Astellas Announces Leadership Changes in U.S. Health Systems Commercial Organization americanpharmaceuticacreview
November 03, 2017
Astellas announced two senior-level changes in its U.S. Commercial organization within the company's Health Systems business unit. James Miteff will be promoted to national vice president, Health Systems Payer & Channel Account Management.
Pfizer, Astellas prostate cancer drug promising in late-stage trial expressbpd
September 18, 2017
Pfizer and Astellas jointly sell Xtandi in the US, while Astellas owns the rights to develop and sell Xtandi outside the US
Astellas announces wind-down of Agensys research operations biospectrumasia
July 28, 2017
Astellas plans to complete the wind-down of Agensys research operations in the first quarter of calendar 2018.
Wayward Astellas comes close to UK industry expulsion pharmaphorum
June 27, 2017
Astellas has failed to heed warnings about not following the UK pharma industry code
Astellas announces decision to discontinue ASP8273 treatment pharmaasia
May 31, 2017
Astellas announces discontinuation of ASP8273 and close randomization for clinical study Protocol 8273-CL-0302.
Astellas Names Senior Vice President, Head of Medical Affairs Americas americanpharmaceuticalreview
May 15, 2017
Astellas announced the promotion of Shontelle Dodson, Pharm.D., to senior vice president and head of Medical Affairs Americas, effective May 15, 2017. Dodson previously served as vice president of Medical Excellence within the global Medical Affairs organ
Astellas Announces Leadership Promotions in Development Organization americanpharmaceuticalreview
May 02, 2017
Astellas announced three senior-level promotions within its Development organization.
Astellas Appoints Three Senior Development Heads contractpharma
May 02, 2017
Fleishaker, Gronen, and Krivoshik to lead clinical, data, and oncology departments
Astellas Reports FY2016 Financial Results americanpharmaceuticalreview
April 28, 2017
Astellas Pharma announced the financial results for fiscal year 2016 ended March 31, 2017. Sales for the full-year of FY2016 decreased by 4.4% compared to the previous fiscal year, resulting in 1,311.7 billion yen.
Japan's Astellas pharma to acquire Belgium firm Ogeda biospectrumasia
April 10, 2017
Subject to certain conditions, the deal is expected to complete in the second quarter of this year

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page